Questions About Cancer? 1-800-4-CANCER
  • View entire document
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Childhood Hematopoietic Cell Transplantation (PDQ®)

Changes to This Summary (12/12/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Allogeneic Hematopoietic Cell Transplantation (HCT)

Added Gragert et al. as reference 2.

Complications After HCT

Added text to state that high HCT-Charlson Comorbidity Index scores (>3) have been associated with a higher risk of grades 3 to 4 acute graft-versus-host disease (cited Sorror et al. as reference 5).

Added text about the recommendations on the diagnosis and management of veno-occlusive disease published by the British Society for Blood and Marrow Transplantation (cited Dignan et al. and Ruutu et al. as references 17 and 18, respectively).

Added Styczynski et al. as reference 30.

Late Effects After HCT in Children

Added Uhlving et al. as reference 131.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: December 12, 2014